ADI |
Acceptable Daily Intake |
ADME |
Absorption, Distribution, Metabolism, Excretion |
AMKL |
Acute Megakaryoblastic Leukaemia |
ARfD |
Acute Reference Dose |
BMD |
Benchmark Dose |
BMDL |
Lower confidence Limit of the Benchmark Dose |
BMR |
Benchmark Response |
CDKs |
Cyclin‐dependent kinases |
cGAMP or cyclic GMP–AMP |
Cyclic guanosine monophosphate–adenosine monophosphate |
cGAS |
Cyclic guanosine monophosphate–adenosine monophosphate synthase |
CREST |
Calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly and telangiectasia |
CSGMT |
Collaborative Study Group of the Micronucleus Test |
CytB |
Cytochalasin B |
FISH |
Fluorescence in situ hybridisation |
GIT |
Gastrointestinal Tract |
GIT MN assay |
Gastrointestinal Tract Micronucleus assay |
HBGV |
Health‐Based Guidance Value |
IWGT |
International Workshop on Genotoxicity Test |
IWGTP |
International Workshop on Genotoxicity Test Procedures |
JEMS |
Japanese Environmental Mutagen Society |
MMS |
Mammalian Mutagenicity Study |
MN |
Micronucleus/micronuclei |
MOE |
Margin of Exposure |
NOAEL |
No Observed Adverse Effect Level |
NOEL |
No Observed Effect Level |
OECD |
Organisation for Economic Co‐operation and Development |
OECD TG 471 |
Bacteria reverse mutation text guideline (AMES test) |
OECD TG 474 |
The mammalian erythrocyte micronucleus test guideline |
OECD TG 487 |
In vitro mammalian cell micronucleus test guideline |
OECD TG 488 |
Transgenic rodent assay |
OECD TG 489 |
In vivo mammalian alkaline comet assay |
SC |
Scientific Committee |
TDI |
Tolerable Daily Intake |
ToR |
Terms of Reference |
TTC |
Threshold of Toxicological Concern |
UF |
Uncertainty Factor |
WHO |
World Health Organization |